The Role of SETBP1 in Gastric Cancer: Friend or Foe

Fujin Fang; Chengyou Liu; Qiong Li; Rui Xu; Tiantian Zhang; Xiaobing Shen

doi:10.3389/fonc.2022.908943

The Role of SETBP1 in Gastric Cancer: Friend or Foe

Front Oncol. 2022 Jul 11:12:908943. doi: 10.3389/fonc.2022.908943. eCollection 2022.

Authors

Fujin Fang^{1

2}, Chengyou Liu³, Qiong Li^{1

2}, Rui Xu^{1

2}, Tiantian Zhang⁴, Xiaobing Shen^{1

2}

Affiliations

¹ Key Laboratory of Environmental Medical Engineering and Education Ministry, School of Public Health, Southeast University, Nanjing, China.
² Department of Preventive Medicine, School of Public Health, Southeast University, Nanjing, China.
³ Department of Medical Engineering, Nanjing First Hospital, Nanjing, China.
⁴ Department of Clinical Laboratory, The Third People's Hospital of Bengbu, Bengbu, China.

Abstract

Background: Gastric cancer (GC) remains a common disease with a poor prognosis worldwide. The SET binding protein 1 (SETBP1) has been implicated in the pathogenesis of several cancers and plays a dual role as an oncogene and a tumor suppressor gene. However, the role and underlying mechanism of SETBP1 in GC remain unclear.

Materials and methods: We used next-generation RNA sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) to explore the correlation between SETBP1 expression and tumor progression. We then quantified SETBP1 expression in GC cells with real-time quantitative polymerase chain reactions (RT-qPCR). The chi-square test and logistic regression were used to assess the correlation between SETBP1 expression and clinicopathological features. Kaplan-Meier survival analysis and Cox proportional hazards regression model were used to assess the relationship between SETBP1 expression and survival. Finally, gene set enrichment analyses (GSEA) were used to examine GC-related signaling pathways in low and high SETBP1 expressing samples.

Results: We found SETBP1 expression levels in GC tissues to be significantly lower than in adjacent non-tumor tissues in the TCGA database. In addition, SETBP1 expression differed significantly between groups classified by tumor differentiation. Furthermore, SETBP1 expression in diffuse-type GC was significantly higher than in intestinal-type GC. However, it did not differ significantly across pathological- or T-stage groups. RT-qPCR and comprehensive meta-analysis showed that SETBP1 expression is downregulated in GC cells and tissues. Interestingly, SETBP1 expression in poorly- or un-differentiated GC cells was higher than in well-differentiated GC cells. Moreover, the chi-square test and logistic regression analyses showed that SETBP1 expression correlates significantly with tumor differentiation. Kaplan-Meier curves indicated that patients with relatively high SETBP1 expression had a poor prognosis. Multivariate analyses indicated that SETBP1 expression might be an important predictor of poor overall survival in GC patients. GSEA indicated that 20 signaling pathways were significantly enriched in samples with high and low SETBP1 expression.

Conclusion: SETBP1 may play a dual role in GC progression.

Keywords: GSEA; SETBP1; TCGA; gastric cancer; prognostic marker.